Navigation Links
DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC

l block the uptake of the toxin before entering the bloodstream and reaching peripheral nerves. BT-VACC™ originated from the work of Lance Simpson, PhD, and has been exclusively licensed from Jefferson Medical College.

"These results are a major step forward and represent the first demonstration of a multivalent vaccine that is active by the mucosal route," said Christopher J. Schaber, PhD, President and CEO of DOR. "We think that these results in animals demonstrate the potential of developing subunit vaccines that can be given by a mucosal route, avoiding the use of needles and injections, with greater ease of administration and convenience for the provider and the patient. Such vaccines would further have the advantage to stimulate antibodies that block absorption of toxin into the body. We expect that the successful development of a multivalent oral botulinum toxin vaccine that can be applied to rapidly deployable mass immunization programs will be a major step forward in Biodefense countermeasures."

"These results are valuable for two reasons," added Lance L. Simpson, PhD, Professor of Medicine and Director of the Center for Research on Bioterrorism and Biodefense at Jefferson Medical College. "First, they are a clear demonstration that it is feasible to create an inhalation or intranasal vaccine against the three botulinum serotypes that are of greatest concern to human health. Second, and looking toward the future, the results are a promising indicator that it should be possible to create an oral vaccine. There is a consensus among immunologists and public health officials that oral vaccination is one of the most desirable ways to protect vulnerable populations against toxic substances."

Because the toxin naturally enters lung and intestinal tissues very efficiently, it is specifically possible to engineer a botulinum vaccine that can be administered orally or via nasal administration. Unpublished results have also shown that oral a
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:12/1/2008)...O, Dec. 1 TargeGen has announced t...from a multi-center, US-based clinical,trial of T... been scheduled at,the 2008 American Society of H... presentation are as follows:, Title: ...vailable, JAK2-Selective I...
(Date:12/1/2008)...stinence is still the best policy , , ROCH...new study from Mayo Clinic finds the use of the dr...holic hepatitis, an acute inflammation of the live...results of the study are published in the December...urnal.org/ ). , , VIDEO ALERT: Additional ...
(Date:12/1/2008)...O, Dec. 1 Vical Incorpor... of a $1.0 million milestone payment from Merck &a...of a Phase I clinical trial of an investigational ...accine is based on Vical,s DNA gene delivery techn...iptase (hTERT). hTERT is the subject of separate l...
(Date:11/27/2008)...y finds the majority of acute lymphoblastic leukem... at the time of diagnosis , , MEMPHIS, Tenn...t St. Jude Children,s Research Hospital have ident...lls of children with acute lymphoblastic leukemia ...hway to designing treatments for ALL relapse in ch...
Breaking Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Progress toward new storage media 8631 1Progress toward new storage media 8631 2Anadys Pharmaceuticals to Present at Bio Investor Forum 27824 1Anadys Pharmaceuticals to Present at Bio Investor Forum 27824 2MU researchers advance health communication for at risk populations 27821 1MU researchers advance health communication for at risk populations 27821 2Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 1Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 2Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 3Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 4
... Since the level of blood oxygenation can be an es... of hemoglobin levels in the clinical setting is o...o incorporate sophisticated technology into easily...several manufacturers offer prompt assessment of h..., Calif., says that its HemoCue Hemoglobin Test Sy...
... Although it may still seem radically innovative i...ated production in the manufacturing sector had be..., for example, automated lines fabricate sub-assem...an oversight. The result has been vastly improved ...ive returns in profit and productivity. These days...
Other Medicine Technology:Hemoglobin Testing at the Point of Care 2Hemoglobin Testing at the Point of Care 3Lab Automation Networks Proliferating 2Lab Automation Networks Proliferating 3Lab Automation Networks Proliferating 4
(Date:12/2/2008)...N, China, Dec. 2 /PRNewswire-Asia-FirstCall/ -- Ch..." or "the Company") (Nasdaq: CSKI ), a leading,...over-the-counter drugs in,the People,s Republic o...Stanley) Hao was appointed Chief Financial Officer...,s Board of Directors. He replaces Yu-kun Zhang, ...
(Date:12/2/2008)...BURGH, Dec. 2 Mylan Inc....ubsidiary, Mylan Pharmaceuticals Inc., have entere...aceuticals Corp., Novartis,Corp. and Novartis Int...neric,version of Novartis, Femara(R). , My...ted: "We are very,pleased to have reached this ag...
(Date:12/2/2008)...NVILLE, Calif., Dec. 2 In response...n A Toxicity, Frequent Respiratory Infections, and...ovember 11th by 16 well known supplement experts, ... oil products pose no threat or compromise to cons...solutions that are low in natural Vitamin A. Accor...
(Date:12/2/2008)... SPEAK to collect and dissemin... Bellevue, Wash. (PRWEB) December ...ced the launch of a new initiative to focus public...eness . The official kick-off of SPEAK will occur ...acists (ASHP) 2008 Midyear Clinical Meeting, to be...
Breaking Medicine News(10 mins):Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2Health News:Pharmacy OneSource Launches SPEAK Initiative to Promote Medication Safety Awareness 2
...ave limited benefit in the first-line treatment of...// according to a report in the April issue of Arc...rnals. However, a second report in the same issue ...may be effective in patients with another ulcer-ca...
...n (FDA) is alerting consumers to possible serious ...aminated with a deadly bacterium, Clostridium botu...lly fatal illness. The olives are made by Charlie ... and are being recalled by the manufacturer. No il...
...for liver cancer, says a US study. Using DNA isol... researchers at Columbia University's Mailman Scho...rly detection of liver cancer, says the study publ...of Clinical Cancer Research. The scientists exami...
...ke is an effective way of identifying prostate can...teoporosis, according to a research.// Researcher... Barcelona, Spain, looked at a cross-section of 37...t were receiving androgen-deprivation therapy (ADT...
Other Medicine News:Health News:Clinical Studies Evaluate Potential Treatments for Mouth Ulcers 2Health News:Clinical Studies Evaluate Potential Treatments for Mouth Ulcers 3Health News:FDA Urgently Warns Consumers About Health Risks of Potentially Contaminated Olives 2Health News:Blood DNA Predicts Liver Cancer Early 2Health News:Measuring Calcium Intake Help to Identify Osteoporosis in Prostate Cancer Patient 2
The Medtronic StableMapr catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing associated
The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available.
...heter is specifically designed for use with our CA...able NAVI-STAR catheter houses a Biosense Webster ..., exact location points from within the heart whil...rmation. The NAVI-STAR electro-anatomical navigati...
For Tricuspid Mapping. Biosense Webster offers a complete line of specialty 20-pole catheters for mapping in the atrium. The HALO XP 20-pole deflectable catheter is designed for simple placement and
Medicine Products: